Saluda Medical Overview
Pro stress-test →Saluda Medical is a global company revolutionizing the field of neuromodulation with an emerging portfolio of therapies driven by advanced closed-loop technologies designed to treat debilitating neurological disorders. The company's first product, the Evoke® System, is the only ECAP-controlled closed-loop spinal cord stimulation (SCS) system and is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain, and leg pain.
Strategic Profile
Pro stress-test →The Evoke System instantaneously reads, records, and responds to the nerves' response to stimulation to provide continually optimized therapy and is proven to be superior to open-loop SCS for the treatment of overall trunk and/or limb pain. 12-month results from the EVOKE Study, the first double-blind randomized controlled trial (RCT) used in support of Premarket Approval (PMA) in spinal cord stimulation history, were published in The Lancet Neurology and 24-month results have since been published JAMA Neurology. Saluda Medical's latest funding was a Series F round on October 30, 2025, positioning the company for expanded commercialization.
Competitive Landscape
Pro stress-test →Saluda Medical competes with companies including Nalu Medical, Nuvectra and Clearing in the neuromodulation space. As the only ECAP-controlled closed-loop SCS player with published clinical superiority data, Saluda holds differentiation versus traditional open-loop competitors. The market is dominated by established players offering open-loop systems, creating opportunity for closed-loop innovation.
Industry Context
Saluda Medical operates in Closed-loop spinal cord stimulation systems.
Key facts
Founded: 2010 · Headquarters: Bloomington, Minnesota, US · Employees: 483 · Revenue: $20.2M (2026)